Vericiguat did not meet primary endpoint but lowered risk of cardiovascular death in patients with heart failure

Published Date: 03 Sep 2025

Vericiguat did not reduce the risk of cardiovascular mortality and heart failure (HF) hospitalizations in ambulatory patients with HF and reduced ejection fraction (HFrEF) without recent worsening, according to late-breaking ...

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Non-Factor Therapies in Hemophilia: Cutting-Edge Approaches to Individualize Care

2.

FDA approves Blenrep for relapsed or refractory multiple myeloma

3.

X-ray and radar technology combined to reduce cancer screening risks

4.

Extended Maintenance with Imatinib Enhances Disease-Free Survival in High-Risk GIST.

5.

Researchers discuss HER2-low and HER2-zero in breast cancer


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot